PI and Study Director

Principal Investigator (PI)

Principal Investigator Dr. Antonio J. Carcas is a Clinical Pharmacologist with wide experience in clinical trials, drug evaluation and clinical investigation methodology. He is full professor of Clinical Pharmacology and Clinical Investigation at Universidad Autónoma de Madrid. He is member of the Clinic
Pharmacology Research Group from IdiPAZ and has participated in clinical trials of phases I to IV, utilization studies and pharmacovigilance programs. He is member of the Spanish Clinical Research Network (SCReN) and ECRIN, and he Scientific Director and responsible of Pharmacovigilance of La Paz Unit of Clinical Investigation (UICEC), one of the nodes of SCReN. He is also member of the Spanish Pediatric Clinical Trials Network (RECLIP) and the groups of Pharmacogenetic of SCREN and the Spanish Society of Clinical Pharmacology.

Study Director

Study Director Maarten van Dongen is originally a molecular & medical microbiologist. After his PhD in Biochemistry at the University of Amsterdam, The Netherlands, he has worked for the international pharma and biopharma industry in The Netherlands, Switzerland, Finland and Belgium. Later he advised Netherlands and international public and private organizations in the domain of Life Sciences. As an advisor Maarten was increasingly asked to lead large projects in the field of antimicrobial resistance (AMR). In 2015, he was asked by the Dutch Ministry of Health, Welfare and Sports to design a national collaborative structure for the development of new antibiotics. In 2016, together with 12 Dutch organisations, he explored the potential of a new to set up a global information platform on AMR. In 2017 he founded AMR Insights and decided to focus his professional activities on combating the global threat of AMR. AMR Insights informs, educates and connects professionals with the aim to curb Antimicrobial resistance. AMR Insights has the ambition to develop into a global information platform on Antimicrobial resistance.  Maarten is committed to eliminating antimicrobial resistance because he does not accept that millions of innocent people need to die as a result of resistant bacteria and other microorganisms.

Dr Maarten B.M. van Dongen
AMR Insights
Keizersgracht 482, 1017 EG Amsterdam, The Netherlands
Phone +31 (0)20 214 6068
Cell +31 (0)65 155 8068
@ Mail Maarten@AMR-Insights.EU
@ Mail Info@AMR-Insights.EU
Registered in The Netherlands CCT 57963177


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed